Preclinical models for small-cell lung cancer
Prof Anton Berns - Netherlands Cancer Institute, Amsterdam, Netherlands
18 Jun 2020
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
17 Jun 2020
High-dose twice daily thoracic radiotherapy in limited disease small-cell lung c...
Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway
15 Jun 2020
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung can...
Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA
12 Jun 2020
METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer
Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA
12 Jun 2020
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, ...
2 Jun 2020
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer
Prof Benjamin Besse and Dr Alex Spira
2 Jun 2020
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy f...
Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA
31 May 2020
Brigatinib for NSCLC, latest research and overcoming complications
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
29 May 2020
Sym015 shows superior specificity compared to TKIs for NSCLC
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
29 May 2020
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer
Prof Roy Herbst - Yale Cancer Center, New Haven, USA
29 May 2020
Do immune checkpoint inhibitors work in EGFR mutant lung cancer?
Dr Edward Garon - UCLA Medical Center, Santa Monica, USA
22 May 2020
